期刊文献+

重组大肠杆菌生产可溶性MBP融合肝素酶的培养条件优化 被引量:5

Optimization of cultivation conditions of recombinant E.coli for production of soluble MBP-fused heparinase Ⅰ
下载PDF
导出
摘要 为确立肝素酶Ⅰ的高效生产工艺,利用麦芽糖结合蛋白(MBP)与肝素酶Ⅰ融合性能,通过构建相应的表达质粒pMHS,在大肠杆菌方面实现了肝素酶Ⅰ可溶性表达。通过对LB培养基摇瓶培养E.coliTB1(pMHS)的诱导时机、诱导剂用量以及添加葡萄糖、酵母提取物、乙醇、氯霉素和卡那霉素等一系列培养条件的优化,确定了该可溶性肝素酶融合蛋白MBP-hepA的最佳生产条件。 In order to achieve high production of heparinase Ⅰ , which is the most useful enzyme in production of LMWH (Low molecular weight heparin),the plasmid pMHS with recombinant heparinase Ⅰ fused to the Cterminal of maltose binding protein (MBP) was constructed and the soluble expression in E. coli was realized. Based on the constructed vector, optimization of the cultivation conditions using LB medium was carried out, including the induction time, the concentration of the inducer, the additions of glucose, yeast extact, ethanol, chloromycetin (Cm) and kanamycin (Kam)
出处 《生物加工过程》 CAS CSCD 2006年第3期28-32,共5页 Chinese Journal of Bioprocess Engineering
基金 自然科学基金重点项目(20336010)资助
关键词 肝素酶 大肠杆菌 麦芽糖结合蛋白 优化 可溶性表达 heparinase E. coli maltose binding protein (MBP) optimization soluble expression
  • 相关文献

参考文献15

  • 1[1]Yang V C,Linhardt R J,Bernstein H,et al.Purification and characterization of heparinase from Flavobacterium heparinum[ J ].J Biological Chemistry,1985,260:1849-1857.
  • 2[2]Lohse D L,Linhardt R J.Purification and characterization of heparin lyases from Flavobacterium heparinum[ J ].J Biological Chemistry,1992,267:24347-24355.
  • 3[3]Bohmer L H,Pitout M J,Steyn P L,et al.Purification and characterization of a novel heparinase[J].J Biological Chemistry,1990,265:13609-13617.
  • 4石峰,姬胜利,迟延青,张天民.低分子肝素的制备方法及其结构与生物活性的关系[J].中国生化药物杂志,2003,24(2):101-104. 被引量:27
  • 5[5]Langer R,Linhardt R J.An enzymatic system for removing heparin in extracorporeal therapy[ J].Science,1982,217:261-263.
  • 6[6]Silva M E,Dietrich C P.Structure of heparin:Characterization of the products formed from heparin by the action of a heparinase and a heparitinase from Flavobacterium heparinum[J].J Biological Chemistry,1975,250:6841-6844.
  • 7[7]Miao H Q,Elkin M,Aingorn E.Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides[ J].International Journal of Cancer,1999,83:424-431.
  • 8[8]Sasisekharan R,Moses M,Nugent M.Heparinase inhibits neovascularization[J].Proceedings of the National Academy of Sciences of the United States of America,1994,91:1524-1528.
  • 9陈小波.低分子量肝素在血液透析抗凝中应用的进展[J].临床荟萃,1998,13(18):819-821. 被引量:14
  • 10[10]陈银.肝素酶Ⅰ在大肠杆菌中的高效重组表达研究[D].北京:清华大学化学工程系,2005.

二级参考文献20

  • 1王福清,张天民,崔慧斐,许荔新.低抗凝肝素来源低分子肝素的研制及药代动力学[J].中国药学杂志,1994,29(2):99-101. 被引量:4
  • 2朱兰英,吴永贵,毛海萍,安业浩,彭文兴,李欣,曾牡华,陈惠珍.单剂量低分子量肝素在血液透析抗凝中的应用[J].中华肾脏病杂志,1996,12(1):32-35. 被引量:91
  • 3曹跃琼,陶元器,杨春雷.肝素中存在的一个不易被亚硝酸降解的片段[J].中国生化药物杂志,1996,17(1):1-4. 被引量:3
  • 4姬胜利,张天民.肝素与低分子肝素的研究进展[J].中国生化药物杂志,1996,17(5):216-219. 被引量:34
  • 5Lormean JC, Maine M J, Choay J. Oligosacehacides having anti-Xa activity and pharmaceutical composition containing them [ P ]. US4401662, 1983.
  • 6Smith MR. Process for manufacturing low molecular weight heparins by depolymerization of normal heparin [P]. EP 0101041, 1983.
  • 7Yasuo H. Production of low molecular weight heparin [P ]. JP11130801, 1999.
  • 8Linhardt RJ. Analysis of glycosaminoglycans with polysaccharldelyases( Vol 2) [M]. New York: Wiley Interscience: 1994.17-32.
  • 9Fareed J, Jeske W, Hoppensteadt D, et al. Low molecular weight heparins : Pharmceutical profile and product differentiation[J]. Am J Cardiol, 1998, 82 : 3-10.
  • 10Linhardt RJ, Loganathan D, M-Hakim et al. Oligosaccharide mapping of low molecular weight heparins : Structure and activity differences [ J].J Med Chem, 1990, 33: 1639-1645.

共引文献39

同被引文献93

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部